Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about SABS, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Cilgavimab/Tixagevimab (AZD7442) | Coronavirus | Phase 2/3 · NCT04518410 | Completed |
| Interferon Beta-1a Inhalation Solution SNG001 | Coronavirus | Phase 2/3 · NCT04518410 | Completed |
| Anti-SARS-CoV-2 Polyclonal Antibodies SAB-185 | Coronavirus | Phase 2/3 · NCT04518410 | Completed |
| High Dose SAB-142 | Type 1 Diabetes (T1D) | Phase 3 · NCT07670650 | Not yet recruiting |
| Casirivimab/Imdevimab | Coronavirus | Phase 2/3 · NCT04518410 | Completed |
| Camostat | Coronavirus | Phase 2/3 · NCT04518410 | Completed |
| Amubarvimab (BRII-196) | Coronavirus | Phase 2/3 · NCT04518410 | Completed |
| Anti-SARS-CoV-2 Monoclonal Antibodies… | Coronavirus | Phase 2/3 · NCT04518410 | Completed |
| Bamlanivimab | Coronavirus | Phase 2/3 · NCT04518410 | Completed |
| SAB-176 | Influenza A H1N1 | Phase 2 · NCT04850898 | Completed |
| SAB-301 | Middle East Respiratory Syndrome Coronavirus | Phase 1 · NCT02788188 | Completed |
| Single Ascending Dose of SAB-176 | PHA1A | Phase 1 · NCT06435936 | Unknown |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
SABS holds $190M in cash and short-term investments (as of Sep 30, 2026) and burns about $11.4M/quarter from operations, an estimated runway of 49.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SABS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 5%+ holder (13G) | 22,637,108 | 25.13% | 2026-06-30 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 9,609,852 | 10.67% | 2026-08-06 |
| Commodore Capital LP | Institution (13G, 5%+) | 8,948,170 | 9.93% | 2026-06-30 |
| Caligan Partners LP | Institution (13G, 5%+) | 7,967,207 | 8.84% | 2026-06-30 |
| JOHNSON DAVID EDWARD | Institution (13G, 5%+) | 7,967,207 | 8.84% | 2026-03-31 |
| BALYASNY ASSET MANAGEMENT L.P. | Institution (13G, 5%+) | 7,225,439 | 8.02% | 2026-06-30 |
| Perceptive Advisors LLC | Institution (13G, 5%+) | 6,627,501 | 7.36% | 2026-06-30 |
| Adage Capital Management, L.P. | Institution (13G, 5%+) | 6,405,553 | 7.11% | 2026-06-30 |
| Woodline Partners LP | Institution (13G, 5%+) | 5,455,355 | 6.06% | 2026-06-30 |
| BVF PARTNERS L P/IL | Institution (13G, 5%+) | 4,761,906 | 5.29% | 2025-12-31 |
| Millennium Management LLC | 5%+ holder (13G) | 3,432,153 | 3.81% | 2026-04-24 |
| Sessa Capital (Master), L.P. Director · +553,850 options |
Insider | 2,198,457 | 2.44% | 2025-09-29 |
Share count 90,088,831 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SABS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →